PROKARIUM
2.3.2022 10:02:05 CET | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced today it exercised its option with Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois — CHUV) for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.
“This intellectual property is an important milestone for our lead oncology program as it enters clinical development in 2023 and also lays the groundwork for expanding Salmonella immunotherapy into other solid tumors,” said Livija Deban, PhD, Chief Scientific Officer of Prokarium. “Microbial immunotherapy is the gold standard-of-care in the treatment of bladder cancer. However, high recurrence rates and limited treatment options are currently available for patients. Prokarium is introducing a differentiated, efficacious microbial immunotherapy to a market that has seen little disruption in over 30 years.”
In exchange for the exclusive license, Prokarium will make an upfront payment, as well as additional payments upon achievement of development and commercialization milestones, and, if any product is approved, will pay royalties on net sales.
“Since initiating our collaboration with Prokarium in 2019, our team at the Department of Urology at CHUV has generated a robust preclinical data package demonstrating that Prokarium’s proprietary Salmonella bacteria generates quantitatively and qualitatively superior immune responses with different kinetics compared to the standard-of-care,” said Dr Denise Nardelli-Haefliger, Head of the Urology Research Unit. “Together with Prof Patrice Jichlinski, Prof Beat Roth, Dr Ilaria Lucca and Dr Sonia Domingos-Pereira, we are thrilled to see that the results of our collaboration have the potential to expand the disease-free interval and improve quality of life in patients with non-muscle invasive bladder cancer (NMIBC).”
About Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder cancer represents 5% of all new cancer cases in the US and accounts for 550,000 new cases yearly worldwide. The clinical staging is determined by the depth of invasion into the bladder wall. More than 70% of cases are diagnosed at an early stage, also known as non-muscle invasive bladder Cancer (NMIBC). Despite early diagnosis, the only approved therapies are Bacillus Calmette-Guérin (BCG), which often faces shortages, and chemotherapy, both delivered intravesically. Because of its high incidence and the limited number of treatment options, a huge unmet medical need remains in NMIBC.
About the Lausanne University Hospital - CHUV
The CHUV, Lausanne University Hospital, is one of the five university hospitals in Switzerland. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching. The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). The CHUV has been recognized as one of the World’s 10 best hospitals according to the 2021 ranking of Newsweek magazine. It is with enthusiasm, that the Chairman of the Department of Urology, Prof Beat Roth, will pursue and support the research and studies with this novel treatment for bladder cancer.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Impartner Recognized as a Leader in G2 Summer 2026 Enterprise Grid® for Partner Relationship Management4.6.2026 15:00:00 CEST | Press release
Named a G2 Leader in both Partner Relationship Management and Through-Channel Marketing, reflecting strong customer satisfaction and enterprise momentum. Impartner, the world’s leading partner revenue orchestration platform, today announced it has been named a Leader in the G2 Summer 2026 Enterprise Grid® Report for Partner Relationship Management (PRM). The recognition underscores Impartner’s strong customer validation and continued momentum among enterprise organizations managing large-scale partner ecosystems and indirect sales channels. In the Summer 2026 report, Impartner earned Leader status based on strong customer satisfaction and adoption across organizations operating at scale. G2’s findings show a 4.5 out of 5-star rating from more than 500 verified reviews, with 91% of users indicating they would recommend the platform. Customers gave high marks for key capabilities, including Role-Based Permissions, Deal Management, and Content Repository, with Ease of Doing Business With
Fortegra Appoints Mark Rattner as President4.6.2026 15:00:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., today announced the appointment of Mark Rattner as President. Mr. Rattner, who previously served as Executive Vice President and Chief Underwriting Officer, Insurance, brings a decade of Fortegra leadership and long-standing relationships with reliable distribution partners to his expanded role. Drawing on disciplined underwriting expertise built over a career spanning more than three decades, Mr. Rattner is focused on delivering the highest value and consistent results to the agents and brokers the company serves. His appointment reflects Fortegra’s continued investment in the people and partnerships that drive long-term, sustainable profitability. “Mark has been central to building Fortegra into the company it is today. His industry experience, knowledge, and trade craft make him the right person for this role. As we continue to evolve, Mark will enhance our partners
Tsuno Rice Fine Chemicals: Comparative Absorption Study of Rice Bran-Derived “Rice Magnesium” Reveals New Insights into Its Gradual, Sustained Absorption Profile4.6.2026 15:00:00 CEST | Press release
Tsuno Rice Fine Chemicals Co., Ltd. announced findings from an in-house human study showing that its proprietary rice bran-derived ingredient, “Rice Magnesium,” delivers gradual, sustained magnesium absorption compared with other magnesium sources. The results suggest potential benefits for sleep maintenance, muscle fatigue management during prolonged exercise, and gentler digestive tolerance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604576648/en/ Tsuno Rice Fine Chemicals: Differences in Absorption Among Magnesium Supplements Product Name: Rice Magnesium Most magnesium ingredients currently available on the market are mineral-derived. In contrast, Rice Magnesium is a rare plant-based magnesium ingredient sourced from rice bran, developed through Tsuno’s long-standing rice bran research. Composition: Magnesium phosphate Source Material: Japanese rice bran Study Background Magnesium is an essential mineral involved i
CSC Adds .BRAND Advisory and Domain Security Services to CrowdStrike Marketplace through Expanded Partnership4.6.2026 15:00:00 CEST | Press release
Expanded offering provides critical domain management and security support CSC, the world's leading enterprise-class domain registrar and online brand protection provider, today announced that its .BRAND services are now available on the CrowdStrike Marketplace. Building on CSC’s existing integration with the CrowdStrike Falcon® platform, this new listing provides enterprises with advanced domain advisory and security support to help them navigate the ICANN New gTLD Program application window, open now until August 12, 2026. As artificial intelligence (AI) drives increased activity across digital assets and domain name system (DNS) infrastructure, managing domain portfolios is a key part of enterprise cybersecurity. With CSC’s .BRAND services available on the CrowdStrike Marketplace, customers can centralize control and reduce reliance on third-party domains. By establishing a DNS trust anchor with centralized authentication aligned to zero-trust principles, organizations that use .BRA
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It4.6.2026 14:33:00 CEST | Press release
Peer reviewed life cycle assessment published in the Journal of Dentistry (ISO 14040/14044-compliant) finds most impact comes from clinical care pathways, making prevention at home the biggest lever to improving outcomes for patients and the environment. Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601115251/en/ Oral-B iO9 Black The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the first time quantifies the environmental burden associated with the presence of periodontal disease, its progression and the associated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom